All posts by: Michael Zand

About Michael Zand

Immunotherapy Promising in Parkinson’s Disease – Medscape

Continue reading

2017-06-13 NEWS

Medscape

Immunotherapy Promising in Parkinson’s Disease
Medscape
VANCOUVER — Immunotherapy using a novel monoclonal antibody appears to be a promising new approach to treating Parkinson’s disease (PD). A phase 1b study of a humanized IgG1 monoclonal antibody directed against α-synuclein (PRX002, …

Continue reading

2017-06-13 NEWS

Medscape

Immunotherapy Promising in Parkinson’s Disease
Medscape
VANCOUVER — Immunotherapy using a novel monoclonal antibody appears to be a promising new approach to treating Parkinson’s disease (PD). A phase 1b study of a humanized IgG1 monoclonal antibody directed against α-synuclein (PRX002, …

Continue reading

2017-06-13 NEWS

TCR(2) Therapeutics Presents Positive Solid Tumor Data for its Novel TRuC™ Engineered T Cell Therapies at the …
PR Newswire (press release)
CAMBRIDGE, Mass., June 13, 2017 /PRNewswire/ — TCR2 Therapeutics Inc. announced data today on two of its TRuC™ programs that showed superior persistence and anti-tumor activity of the company’s TRuC™-T cells compared to CART cells in …

Continue reading

2017-06-13 NEWS

PR Newswire (press release)

Stem Cell Therapy Becomes Law in Texas
PR Newswire (press release)
LA JOLLA, Calif., June 13, 2017 /PRNewswire/ — House Bill (HB 810) on stem cell therapy has passed in the Texas state legislature and become law. Patients in Texas will now have access to this “Right to Try” innovative form of therapy for those

Continue reading

2017-06-13 NEWS

Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and …
Nasdaq
“We believe that adding evofosfamide to certain immunotherapies has the potential to render some of the most therapeutically resistant cancers more sensitive to the immunotherapy and we are excited to have dosed the first patient in this study,” said

and more »

Continue reading

2017-06-13 NEWS

Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and …
GlobeNewswire (press release)
“We believe that adding evofosfamide to certain immunotherapies has the potential to render some of the most therapeutically resistant cancers more sensitive to the immunotherapy and we are excited to have dosed the first patient in this study,” said

and more »

Continue reading

2017-06-13 NEWS

WFAA

Oral Immunotherapy may be answer to food allergy issues
WFAA
Children with food allergies used to only have one option: avoid what you’re allergic to. But thanks to food allergy research, there’s another solution. Like any mom, Christine Cassen will do anything to protect her children. Chloe is eight and Emma is

and more »